Association of three single nucleotide polymorphisms of interleukin -35 for detection and prediction of women with breast cancer in Erbil city

Zhian Ismael A.  Daham; Suhaila  N. Darogha

doi:10.21271/ZJPAS.34.1.6

Authors

Zhian Ismael A. Daham Department of Biology ,College of Education, Salahaddin University- Erbil, Iraq
Suhaila N. Darogha Department of Biology ,College of Education, Salahaddin University- Erbil, Iraq

DOI:

https://doi.org/10.21271/ZJPAS.34.1.6

Keywords:

Breast cancer, Interleukin 35, Single Nucleotide Gene polymorphism, Age and BMI

Abstract

Background: Interleukins have a substantial role in the improvement of many types of cancer. Interleukin genes have many single nucleotide polymorphisms (SNPs) that may alter protein synthesis or function, and many of them have been related to cancer risk. The objective of this study is to determine whether particular SNPs in interleukin 35 contributed to breast cancer susceptibility and severity.

Methods: For IL-35 interleukin SNP detection, seventy benign breast disease, BC patients, 70 malignant BC and control healthy donors were obtained from patient’s sera. We utilized an allelic discrimination approach that could genotype a large number of samples quickly. The long-term consequences and clinico-pathological aspects were also investigated.

Results: study is focused on three distinct IL-35 SNPs (IL12 G/A, IL12 ACT, and EBI3) and revealed a substantial upsurge in the chance of developing malignant breast cancer exclusively when compared to the control group. Both benign and malignant patients had significantly lower blood levels of IL-35 than controls (p< 0.05). Regardless of your age or BMI, there are a few things to consider (BMI) on the level of serum IL-35.

Conclusion: Polymorphisms in the interior of key interleukin genes (IL12 ACT, IL12 G/A & EBI3) seem to play a substantial complete role in breast cancer vulnerability or strictness.

References

AL-JANABI, A. A. H. S., NASEER, Z. H. & HAMODY, T. A. 2017. Epidemiological study of cancers in Iraq-Karbala from 2008 to 2015. International Journal of Medical Research & Health Sciences, 6, 79-86.

ALI, E. T., MASRI, M. A. M., SIDDIG, E. E., AHMED, A., MUNEER, M. S., MOHAMED, N. S. & EDRIS, A. M. M. 2020. Immunohistochemical expression of interleukin-17 and hormonal receptors in benign and malignant breast lesions. BMC Research Notes, 13, 1-6.

ALSHASHIMI, M. M. Y. & WANG, X. J. 2014. Breast cancer in Iraq, incidence trends from 2000S2009. Asian Pacific Journal of Cancer Prevention, 15, 281-286.

MCANDREW, N.P.; BOTTALICO, L.; MESAROS, C.; BLAIR, I.A.; TSAO, P.Y.; ROSADO, J.M.; GANGULY, T.; SONG , S.J.; GIMOTTY, P.A.; MAO, J.J. AND DEMICHELE, A.2021. Effects of systemic inflammation on relapse in early breastcancer. npj Breast Cancer (2021) 7:7

BRAY, F., FERLAY, J., SOERJOMATRAM, I., SIEGEL, R. L., TORRE, L. A. & JEMAL, A. 2018. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. . CA CANCER J. CLIN. 68, 394–424.

CHANG, J. S., WIEMELS, J. L., CHOKKALINGAM, A. P., METAYER, C., BARCELLOS, L. F., HANSEN, H. M., ALDRICH, M. C., GUHA, N., URAYAMA, K. Y. & SCÉLO, G. 2010. Genetic polymorphisms in adaptive immunity genes and childhood acute lymphoblastic leukemia. Cancer Epidemiology and Prevention Biomarkers, 19, 2152-2163.

CHOI, J., LEUNG, P. S., BOWLUS, C. & GERSHWIN, M. E. 2015. IL-35 and autoimmunity: a comprehensive perspective. Clinical reviews in allergy & immunology, 49, 327-332.

GENE CARDS 2021. The human gene database.

EL-GENDY, S.G.; EL-SABAA, E.M.W.; EL-FEKY, M.A.; SHABAAN H. AHMED, S.H. AND SAMIR S. M. EID, S.S.M. 2019. Plasma Levels of Interleukin-35 and its Association with Clinical Features of Breast Cancer Patients at Assiut University Hospitals.The Egyptian Journal Of Immunology. 26 (1): 121-128.

HAMIDINIA, M., BOROUJERDNIA, M. G., TALAIEZADEH, A., SOLGI, G., ROSHANI, R., IRANPRAST, S. & KHODADADI, A. 2015. Increased P-35, EBI3 transcripts and other Treg markers in peripheral blood mononuclear cells of breast cancer patients with different clinical stages. Advanced pharmaceutical bulletin, 5, 261.

HAO, S., CHEN, X., WANG, F., SHAO, Q., LIU, J., ZHAO, H., YUAN, C., REN, H. & MAO, H. 2018. Breast cancer cell–derived il-35 promotes tumor progression via induction of il-35-producing induced regulatory T cells. Carcinogenesis, 39, 1488-1496.

JIANG, J. & LIU, X. 2018. Upregulated EBI3 correlates with poor outcome and tumor progression in breast cancer. Oncology research and treatment, 41, 111-115.

KÅRVATN, M. H., VRBANEC, J., KULIC, A., KNEZEVIC, J., PETRICEVIC, B., BALEN, S., VRBANEC, D. & DEMBIC, Z. 2012. Single nucleotide polymorphism in the interleukin 12B gene is associated with risk for breast cancer development. Scandinavian journal of immunology, 76, 329-335.

LIU, K., HUANG, A., NIE, J., TAN, J., XING, S., QU, Y. & JIANG, K. 2021. IL-35 Regulates the Function of Immune Cells in Tumor Microenvironment. Frontiers in Immunology, 12, 2004.

LONG, C., AMOASII, L., MIREAULT, A. A., MCANALLY, J. R., LI, H., SANCHEZ-ORTIZ, E., BHATTACHARYYA, S., SHELTON, J. M., BASSEL-DUBY, R. & OLSON, E. N. 2016. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science, 351, 400-3.

MATOULKOVA, E., MICHALOVA, E., VOJTESEK, B. & HRSTKA, R. 2012. The role of the 3'untranslated region in post-transcriptional regulation of protein expression in mammalian cells. RNA biology, 9, 563-576.

MIRLEKAR, B. & PYLAYEVA-GUPTA, Y. 2021. IL-12 Family Cytokines in Cancer and Immunotherapy. Cancers, 13, 167.

PISTINER, M., HUNNINGHAKE, G. M., SOTO-QUIROS, M. E., AVILA, L., MURPHY, A., LASKY-SU, J., SCHUEMANN, B., KLANDERMAN, B. J., RABY, B. A. & CELEDÓN, J. C. 2008. Polymorphisms in IL12A and cockroach allergy in children with asthma. Clinical and Molecular Allergy, 6, 1-7.

SIEGEL, R. L., MILLER, K. D., GODING SAUER, A., FEDEWA, S. A., BUTTERLY, L. F., ANDERSON, J. C., CERCEK, A., SMITH, R. A. & JEMAL, A. 2020. Colorectal cancer statistics, 2021. CA: a cancer journal for clinicians, 70, 145-164.

SUNG, H.; FERLAY, J.; SIEGEL, R.L.; LAVERSANNE, M.; SOERJOMATARAM, I.; JEMAL, A.; BRAY, F. 2021. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA CANCER J. CLIN.71:209–249.

WOLFE, A. R., TRENTON, N. J., DEBEB, B. G., LARSON, R., RUFFELL, B., CHU, K., HITTELMAN, W., DIEHL, M., REUBEN, J. M. & UENO, N. T. 2016. Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models. Oncotarget, 7, 82482.

XUE, W., YAN, D. & KAN, Q. 2019. Interleukin-35 as an emerging player in tumor microenvironment. Journal of Cancer, 10, 2074.

YAZDANI, Z., RAFIEI, A., GOLPOUR, M., ZAFARI, P., MOONESI, M. & GHAFFARI, S. 2020. IL‐35, a double‐edged sword in cancer. Journal of cellular biochemistry, 121, 2064-2076.

ZAIDI, Z. & DIB, H. A. 2019. The worldwide female breast cancer incidence and survival, 2018. AACR.

ZHAO, Z., CHEN, X., HAO, S., JIA, R., WANG, N., CHEN, S., LI, M., WANG, C. & MAO, H. 2017a. Increased interleukin-35 expression in tumor-infiltrating lymphocytes correlates with poor prognosis in patients with breast cancer. Cytokine, 89, 76-81.

ZHAO Z, CHEN X, HAO S, JIA R, WANG N, CHEN S, LI M, WANG C, MAO H.2017b. Increased interleukin-35 expression in tumor infiltrating lymphocytes correlates with poor prognosis in patients with breast cancer. Cytokine 89: 76–81.